Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids

The circulating nonspecific immune complexes, complement system peptides and auto-antibodies may induce inflammatory/ thrombotic events at the placenta and impairment of endometrial receptivity as well as disturbed fetal perfusion in Inflammatory Bowel Disease (IBD) cases. The aim of the case seri...

Full description

Bibliographic Details
Main Authors: Kemal Beksac, Gokcen Orgul, Gul Sema Can, Ahmet Oktem, Taylan Kav, Mehmet Sinan Beksac
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2017-11-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
Online Access:https://jcdr.net/articles/PDF/10900/24683_CE[Ra1]_F(DK)_PF1(AG_TG_SS)_PFA(MJ_GG)_PFA2(MJ_GG).pdf
id doaj-ac448356f123429b84c918167e102935
record_format Article
spelling doaj-ac448356f123429b84c918167e1029352020-11-25T02:23:30ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2017-11-011111QR01QR0310.7860/JCDR/2017/24683.10900Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and CorticosteroidsKemal Beksac0Gokcen Orgul1Gul Sema Can2Ahmet Oktem3Taylan Kav4Mehmet Sinan Beksac5Resident, Department of General Surgery, Ankara Oncology Hospital, Ankara, Turkey.Resident, Department of Obstetrics and Gynaecology, Division of Perinatology, Hacettepe University, Ankara, Turkey.Resident, Department of Obstetrics and Gynaecology, Division of Perinatology, Hacettepe University, Ankara, Turkey.Resident, Department of Paediatrics, Division of Neonatology, Hacettepe University, Ankara, Turkey.Professor, Department of Gastroenterology, Hacettepe University, Ankara, Turkey.Professor, Department of Obstetrics and Gynaecology, Division of Perinatology, Hacettepe University, Ankara, Turkey.The circulating nonspecific immune complexes, complement system peptides and auto-antibodies may induce inflammatory/ thrombotic events at the placenta and impairment of endometrial receptivity as well as disturbed fetal perfusion in Inflammatory Bowel Disease (IBD) cases. The aim of the case series was to assess the effect of “Low Molecular Weight Heparin” (LMWH) and Low Dose Corticosteroids (LDC) against possible thromboembolic and inflammatory processes happening at the maternal fetal interface and to assess their efficiency in pregnancy outcomes. Nine cases of IBD, referred during the first trimester of their pregnancies, were retrospectively evaluated {Ulcerative Colitis (UC) (n=7) and Crohn’s Disease (CD) (n=2)}. Patients were under aminosalicylate treatment (eight cases mesalamine and one case sulfasalazine) during their admittance to the program and were all in remission. Aminosalicylate treatment was stopped between 8th and 12th gestational weeks and then continued until the appearance of early signs of uterine contractions and/or fetal “discomfort/distress”. Following tests for thrombophilia, patients presenting risk factors were included to the study group and were given low dose LMWH (Enoxaparine 1x2000 Anti-XA IU/0.2 ml/day), prophylaxis plus LDC (Methylprednisolone 4 mg/day). The mean age of the patients was 28.2±4.05 (20-35). No patient had a flare up during their pregnancy. One UC patient with homozygotic Methylenetetrahydrofolate Reductase (MTHFR) 677 polymorphism experienced preterm premature rupture of membranes (PPROM) at the 31th gestational week and was delivered at 32nd gestational week by caesarean section. The other eight cases also delivered between 36-39th gestational weeks by caesarean section due to obstetrical reasons and/or fetal distress. All neonates were discharged from hospital without any complications. Mean gestational age at birth was 258 days (36 weeks 6 days) and mean birthweight was 2772.2±619.3 grams (1530-3670). In this small case series we were able to obtain successful pregnancy outcomes with the current protocol. Both UC and CD have potential risks of affecting “endothelial/trophoblastic/epithelial” tissues of placenta, impairing endometrial receptivity or fetal perfusion. Control of autoimmune inflammatory processes and thrombotic events by combination of low dose LMWH and LDC may maintain better pregnancy outcome without exacerbation of the IBD. https://jcdr.net/articles/PDF/10900/24683_CE[Ra1]_F(DK)_PF1(AG_TG_SS)_PFA(MJ_GG)_PFA2(MJ_GG).pdfcrohn’s diseasepregnancy immunologyulcerative colitis
collection DOAJ
language English
format Article
sources DOAJ
author Kemal Beksac
Gokcen Orgul
Gul Sema Can
Ahmet Oktem
Taylan Kav
Mehmet Sinan Beksac
spellingShingle Kemal Beksac
Gokcen Orgul
Gul Sema Can
Ahmet Oktem
Taylan Kav
Mehmet Sinan Beksac
Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids
Journal of Clinical and Diagnostic Research
crohn’s disease
pregnancy immunology
ulcerative colitis
author_facet Kemal Beksac
Gokcen Orgul
Gul Sema Can
Ahmet Oktem
Taylan Kav
Mehmet Sinan Beksac
author_sort Kemal Beksac
title Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids
title_short Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids
title_full Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids
title_fullStr Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids
title_full_unstemmed Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids
title_sort management of inflammatory bowel disease and pregnancy using prophylactic low dose low molecular weight heparin and corticosteroids
publisher JCDR Research and Publications Private Limited
series Journal of Clinical and Diagnostic Research
issn 2249-782X
0973-709X
publishDate 2017-11-01
description The circulating nonspecific immune complexes, complement system peptides and auto-antibodies may induce inflammatory/ thrombotic events at the placenta and impairment of endometrial receptivity as well as disturbed fetal perfusion in Inflammatory Bowel Disease (IBD) cases. The aim of the case series was to assess the effect of “Low Molecular Weight Heparin” (LMWH) and Low Dose Corticosteroids (LDC) against possible thromboembolic and inflammatory processes happening at the maternal fetal interface and to assess their efficiency in pregnancy outcomes. Nine cases of IBD, referred during the first trimester of their pregnancies, were retrospectively evaluated {Ulcerative Colitis (UC) (n=7) and Crohn’s Disease (CD) (n=2)}. Patients were under aminosalicylate treatment (eight cases mesalamine and one case sulfasalazine) during their admittance to the program and were all in remission. Aminosalicylate treatment was stopped between 8th and 12th gestational weeks and then continued until the appearance of early signs of uterine contractions and/or fetal “discomfort/distress”. Following tests for thrombophilia, patients presenting risk factors were included to the study group and were given low dose LMWH (Enoxaparine 1x2000 Anti-XA IU/0.2 ml/day), prophylaxis plus LDC (Methylprednisolone 4 mg/day). The mean age of the patients was 28.2±4.05 (20-35). No patient had a flare up during their pregnancy. One UC patient with homozygotic Methylenetetrahydrofolate Reductase (MTHFR) 677 polymorphism experienced preterm premature rupture of membranes (PPROM) at the 31th gestational week and was delivered at 32nd gestational week by caesarean section. The other eight cases also delivered between 36-39th gestational weeks by caesarean section due to obstetrical reasons and/or fetal distress. All neonates were discharged from hospital without any complications. Mean gestational age at birth was 258 days (36 weeks 6 days) and mean birthweight was 2772.2±619.3 grams (1530-3670). In this small case series we were able to obtain successful pregnancy outcomes with the current protocol. Both UC and CD have potential risks of affecting “endothelial/trophoblastic/epithelial” tissues of placenta, impairing endometrial receptivity or fetal perfusion. Control of autoimmune inflammatory processes and thrombotic events by combination of low dose LMWH and LDC may maintain better pregnancy outcome without exacerbation of the IBD.
topic crohn’s disease
pregnancy immunology
ulcerative colitis
url https://jcdr.net/articles/PDF/10900/24683_CE[Ra1]_F(DK)_PF1(AG_TG_SS)_PFA(MJ_GG)_PFA2(MJ_GG).pdf
work_keys_str_mv AT kemalbeksac managementofinflammatoryboweldiseaseandpregnancyusingprophylacticlowdoselowmolecularweightheparinandcorticosteroids
AT gokcenorgul managementofinflammatoryboweldiseaseandpregnancyusingprophylacticlowdoselowmolecularweightheparinandcorticosteroids
AT gulsemacan managementofinflammatoryboweldiseaseandpregnancyusingprophylacticlowdoselowmolecularweightheparinandcorticosteroids
AT ahmetoktem managementofinflammatoryboweldiseaseandpregnancyusingprophylacticlowdoselowmolecularweightheparinandcorticosteroids
AT taylankav managementofinflammatoryboweldiseaseandpregnancyusingprophylacticlowdoselowmolecularweightheparinandcorticosteroids
AT mehmetsinanbeksac managementofinflammatoryboweldiseaseandpregnancyusingprophylacticlowdoselowmolecularweightheparinandcorticosteroids
_version_ 1724859252363755520